Incidence of cutaneous malignancy following the concomitant use of ciclosporin and narrowband ultraviolet B phototherapy in patients with vitiligo
- PMID: 40985256
- DOI: 10.1093/ced/llaf428
Incidence of cutaneous malignancy following the concomitant use of ciclosporin and narrowband ultraviolet B phototherapy in patients with vitiligo
Abstract
This nationwide population-based cohort study investigates the incidence of cutaneous malignancies associated with the concomitant treatment of ciclosporin and narrowband ultraviolet B (NBUVB) phototherapy in patients with vitiligo, using the Korean National Health Insurance Service database. Concomitant ciclosporin and NBUVB phototherapy may not significantly increase the incidence of cutaneous malignancies. Given the chronic autoimmune nature of vitiligo and its economic impact, these findings provide novel insights into the potential safety of these combination regimens.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
